Key Highlights

  • The U.S. Food and Drug Administration has completed its evaluation of Imricor’s Manufacturing module and accepted it as closed.
  • The module covers design, manufacturing and quality processes for seven products, including the Vision-MR Ablation Catheter and RF-5000 Ablation Generator and Pump.
  • Closure of the module represents a further milestone in Imricor’s modular Premarket Approval review with the FDA.
  • Final PMA approval remains subject to completion of the remaining FDA reviews and a pre-approval inspection of Imricor’s manufacturing sites.

FDA Manufacturing Review Reaches Milestone

Imricor Medical Systems (ASX:IMR) has received notification from the U.S. Food and Drug Administration that its manufacturing module under the company’s Premarket Approval submission has been evaluated, accepted and formally closed.

The manufacturing module represents one component of Imricor’s modular FDA review process. It addresses the design, manufacturing and quality processes associated with seven products. Six are Imricor products undergoing the PMA process, while the seventh is a third-party product that the company intends to distribute.

The module covers areas including design controls, raw-material receipt and inspection, storage procedures, manufacturing processes, process validation, component and device traceability, and applicable quality-management systems.

Seven Products Covered by the Module

Among the products included in the manufacturing module are Imricor’s Vision-MR Ablation Catheter and RF-5000 Ablation Generator and Pump. The broader product portfolio is focused on electrophysiology procedures conducted under interventional magnetic resonance guidance.

The company has described the manufacturing module as one of the larger and more complex components of its PMA submission because it encompasses seven devices and multiple aspects of their production and quality systems.

With the FDA now considering this module closed, Imricor has completed another defined stage of its regulatory review. Under the modular approach, a module that has been accepted and closed is not expected to undergo another review as part of the final PMA assessment unless changes are subsequently made to its contents.

Final PMA Approval Remains Pending

Despite the manufacturing module reaching closure, the FDA process is not complete. Imricor stated that the agency must still complete its review of all relevant modules before any final PMA approval can be granted.

A further requirement is an FDA pre-approval inspection of the company’s manufacturing sites. The outcome of that inspection, together with satisfactory completion of the remaining regulatory reviews, remains necessary before final approval.

The latest announcement therefore does not report a final FDA approval for the products covered by the PMA process. Instead, it records the completion of one specific part of the broader regulatory pathway.

Portfolio Supports U.S. Commercialisation Plans

Imricor is developing products intended to enable interventional medical procedures under real-time magnetic resonance guidance rather than conventional x-ray fluoroscopy. Its portfolio includes Capital equipment such as the NorthStar Mapping System and Advantage-MR EP Recorder/Stimulator, as well as single-use devices including ablation and diagnostic catheters and other tools used in interventional MR laboratories.

The company stated that it is progressing through both 510(k) and PMA regulatory processes across its electrophysiology device portfolio. Products are already approved in several international markets, including the European Union, Kingdom of Saudi Arabia and New Zealand, while NorthStar and the Vision-MR Diagnostic Catheter have US clearance.

The announcement contains no new revenue, earnings, cash-flow or other financial-performance figures. Consequently, there is no reported increase or decline in financial metrics in this update. The principal development is regulatory, with manufacturing review completed while other steps toward final PMA approval remain outstanding.

Conclusion

Imricor Medical Systems has reached a further regulatory milestone after the FDA accepted and closed the manufacturing module of its PMA submission. The module covers seven products and addresses manufacturing, design and quality-system processes. While the closure removes this component from the expected scope of further PMA review, final approval has not yet been granted. The company still faces completion of the remaining FDA modules and a pre-approval inspection of its manufacturing sites. The latest announcement therefore marks progress within the regulatory process rather than a completed U.S. market approval.